Skip to main content
SpringerLink
Log in

Conventional Treatment of Systemic Lupus Erythematosus

  • Chapter
  • First Online:
Connective Tissue Disease

Part of the book series: Rare Diseases of the Immune System ((RDIS))

  • 1074 Accesses

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with unpredictable course, intermingled with flares and periods of remission. The treatment target of SLE should be remission of systemic symptoms and organ manifestations or attainment of the lowest possible disease activity, measured by at least one validated disease activity index and/or by organ-specific markers. Although the prognosis of the disease has improved in the past decades, current therapies are still associated with treatment-related complications. Moreover, each patient may manifest different symptoms and variable disease activity and severity, as well as therapy-related adverse effects. SLE patients frequently have numerous comorbidities, such as hyperlipidemia and hypertension, which represent risk factors for accelerated atherosclerosis and cardiovascular disease and depression, which can seriously compromise health-related quality of life.

This chapter focuses on conventional management of SLE patients, including nonpharmacologic measures and pharmacological therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Von Feldt JM (1995) Systemic lupus erythematosus. Recognizing its various presentations. Postgrad Med 97:79–83, 86 passim

    Google Scholar 

  2. Gustafsson JT, Svenungsson E (2014) Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 47:67–76

    Article  CAS  PubMed  Google Scholar 

  3. Dua AB, Touma Z, Toloza S et al (2013) Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Curr Rheumatol Rep 15:380–389

    Article  PubMed  Google Scholar 

  4. van Vollenhoven RF, Mosca M, Bertsias G et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958–967

    Article  PubMed  Google Scholar 

  5. Mosca M, Tani C, Aringer M et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69:1269–1274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369

    Article  CAS  PubMed  Google Scholar 

  7. Petri M, Purvey S, Fang H et al (2012) Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 64:4021–4028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ibanez D, Urowitz MB, Gladman DD (2003) Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 30:1977–1982

    PubMed  Google Scholar 

  9. Andrade RM, Alarcon GS, Fernandez M et al (2007) Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum 56:622–630

    Article  PubMed  Google Scholar 

  10. Lopez R, Davidson JE, Beeby MD et al (2012) Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford) 51:491–498

    Article  Google Scholar 

  11. Lehmann P, Homey B (2009) Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev 8:456–461

    Article  CAS  PubMed  Google Scholar 

  12. Takvorian SU, Merola JF, Costenbader KH (2014) Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus. Lupus 23:537–544

    Article  CAS  PubMed  Google Scholar 

  13. Ghaussy NO, Sibbitt W Jr, Bankhurst AD, Qualls CR (2003) Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 30:1215–1221

    PubMed  Google Scholar 

  14. Yuen HK, Cunnigham MA (2014) Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review. Ther Clin Risk Manag 10:775–786

    Article  PubMed  PubMed Central  Google Scholar 

  15. Klack K, Bonfa E, Borba Neto EF (2012) Diet and nutritional aspects in systemic lupus erythematosus. Rev Bras Reumatol 52:384–408

    Article  PubMed  Google Scholar 

  16. Toloza SM, Cole DE, Gladman DD et al (2010) Vitamin D insufficiency in a large female SLE cohort. Lupus 19:13–19

    Article  CAS  PubMed  Google Scholar 

  17. Murdaca G, Orsi A, Spanò F et al (2014) Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev 13:75–84

    Article  CAS  PubMed  Google Scholar 

  18. Mok CC, Ho LY, Fong LS, To CH (2013) Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 72:659–664

    Article  CAS  PubMed  Google Scholar 

  19. Kuruma KA, Borba EF, Lopes MH et al (2007) Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 16:350–354

    Article  CAS  PubMed  Google Scholar 

  20. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28

    Article  CAS  PubMed  Google Scholar 

  21. Tsakonas E, Joseph L, Esdaile JM et al (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7:80–85

    Article  CAS  PubMed  Google Scholar 

  22. Bezerra EL, Vilar MJ, da Trindade Neto PB et al (2005) Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 52:3073–3078

    Article  CAS  PubMed  Google Scholar 

  23. Cavazzana I, Sala R, Bazzani C et al (2009) Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 18:735–739

    Article  CAS  PubMed  Google Scholar 

  24. Fessler BJ, Alarcon GS, McGwin G Jr et al (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52:1473–1480

    Article  PubMed  Google Scholar 

  25. Ibanez D, Gladman DD, Urowitz MB (2005) Adjusted mean systemic lupus erythematosus disease activity index-2K is a predictor of outcome in SLE. J Rheumatol 32:824–827

    PubMed  Google Scholar 

  26. Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:577–583

    Article  CAS  PubMed  Google Scholar 

  27. Urowitz MB, Gladman DD, Tom BD et al (2008) Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 35:2152–2158

    Article  PubMed  Google Scholar 

  28. Zheng ZH, Zhang LJ, Liu WX et al (2012) Predictors of survival in Chinese patients with lupus nephritis. Lupus 21:1049–1056

    Article  CAS  PubMed  Google Scholar 

  29. Jones DW, Wright D, Jankowski TA (2014) Clinical inquiry. What treatments relieve arthritis and fatigue associated with systemic lupus erythematosus? J Fam Pract 63:607–617

    PubMed  Google Scholar 

  30. Walling HW, Sontheimer RD (2009) Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 10:365–381

    Article  PubMed  Google Scholar 

  31. Callen JP (2006) Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol 47:13–27

    Article  PubMed  Google Scholar 

  32. Millard TP, Hawk JL, McGregor JM (2000) Photosensitivity in lupus. Lupus 9:3–10

    Article  CAS  PubMed  Google Scholar 

  33. Bourré-Tessier J, Peschken CA, Bernatsky S et al (2013) Association of smoking with cutaneous manifestations in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65:1275–1280

    Article  Google Scholar 

  34. Sigges J, Biazar C, Landmann A, the EUSCLE Co-Authors et al (2013) Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 12:694–702

    Article  PubMed  Google Scholar 

  35. Avgerinou G, Papafragkaki DK, Nasiopoulou A et al (2012) Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 26:762–767

    Article  CAS  PubMed  Google Scholar 

  36. Pothinamthong P, Janjumratsang P (2012) A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. J Med Assoc Thai 95:933–940

    PubMed  Google Scholar 

  37. Khondker L, Wahab MA, Khan SI (2012) Efficacy of topical application of pimecrolimus cream in the treatment of discoid lupus erythematosus. Mymensingh Med J 21:259–264

    CAS  PubMed  Google Scholar 

  38. Kuhn A, Ruland V, Bonsmann G (2011) Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 65:195–213

    Article  Google Scholar 

  39. Truchuelo MT, Boixeda P, Alcántara J et al (2012) Pulsed dye laser as an excellent choice of treatment for lupus tumidus: a prospective study. J Eur Acad Dermatol Venereol 26:1272–1279

    Article  CAS  PubMed  Google Scholar 

  40. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR (2012) New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 8:522–533

    Article  CAS  PubMed  Google Scholar 

  41. Kuhn A, Ruland V, Bonsmann G (2011) Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol 65:179–193

    Article  Google Scholar 

  42. Chang AY, Piette EW, Foering KP et al (2011) Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 147:1261–1267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Francès C, Cosnes A, Duhaut P et al (2012) Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 148:479–484

    Article  PubMed  Google Scholar 

  44. Hansen CB, Dahle KW (2012) Cutaneous lupus erythematosus. Dermatol Ther 25:99–111

    Article  PubMed  Google Scholar 

  45. Cuadrado MJ, Karim Y, Sanna G et al (2005) Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 118:246–250

    Article  CAS  PubMed  Google Scholar 

  46. Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J (2012) Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 14:R265

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Xiong W, Lahita RG (2014) Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 10:97–107

    Article  CAS  PubMed  Google Scholar 

  48. Privette ED, Werth VP (2013) Update on pathogenesis and treatment of CLE. Curr Opin Rheumatol 25:584–590

    Article  CAS  PubMed  Google Scholar 

  49. Muangchan C, van Vollenhoven RF, Bernatsky SR et al (2015) Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken). doi:10.1002/acr.22589, Epub ahead of print

    Google Scholar 

  50. Sakthiswary R, Suresh E (2014) Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 23:225–235

    Article  CAS  PubMed  Google Scholar 

  51. Artifoni M, Puéchal X (2012) How to treat refractory arthritis in lupus? Joint Bone Spine 79:347–350

    Article  CAS  PubMed  Google Scholar 

  52. Jennekens FG, Kater L (2002) The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 41:605–618

    Article  CAS  Google Scholar 

  53. Hanly JG (2004) ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 13:861–864

    Article  CAS  PubMed  Google Scholar 

  54. Muscal E, Brey RL (2010) Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 28:61–73

    Article  PubMed  PubMed Central  Google Scholar 

  55. Hanly JG (2001) Neuropsychiatric lupus. Curr Rheumatol Rep 3:205–212

    Article  CAS  PubMed  Google Scholar 

  56. McLaurin EY, Holliday SL, Williams P et al (2005) Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64:297–303

    Article  CAS  PubMed  Google Scholar 

  57. Lisnevskaia L, Murphy G, Isenberg D (2014) Systemic lupus erythematosus. Lancet 384:1878–1888

    Article  PubMed  Google Scholar 

  58. Hanly JG, Su L, Farewell V et al (2009) Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 36:1449–1459

    Article  PubMed  Google Scholar 

  59. Hanly JG (2014) Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 10:338–347

    Article  CAS  PubMed  Google Scholar 

  60. O’Neill SG, Schrieber L (2005) Immunotherapy of systemic lupus erythematosus. Autoimmmunity Rev 4:395–402

    Article  CAS  Google Scholar 

  61. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes (1999). Arthritis Rheum 42:599–608

    Google Scholar 

  62. Bertsias GK, Ioannidis JP, Aringer M et al (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69:2074–2082

    Article  CAS  PubMed  Google Scholar 

  63. Mok CC, Lau CS, Wong RW (2003) Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 115:59–62

    Article  CAS  PubMed  Google Scholar 

  64. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L et al (2005) Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 64:620–625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Fernandes Moça Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah AN (2013) Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2:CD002265

    PubMed  Google Scholar 

  66. Tomietto P, D’Agostini S, Annese V et al (2007) Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. J Rheumatol 34:588–591

    PubMed  Google Scholar 

  67. Neuwelt CM (2003) The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 7:173–182

    Article  PubMed  Google Scholar 

  68. Milstone AM, Meyers K, Elia J (2005) Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol 24:394–397

    Article  PubMed  Google Scholar 

  69. Khamashta MA, Cuadrado MJ, Mujic F et al (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997

    Article  CAS  PubMed  Google Scholar 

  70. Muñoz-Rodriguez FJ, Font J, Cervera R et al (1999) Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 29:182–190

    Article  PubMed  Google Scholar 

  71. Tektonidou MG, Ioannidis JP, Boki KA et al (2000) Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. Q J Med 93:523–530

    Article  CAS  Google Scholar 

  72. Ruiz-Irastorza G, Hunt BJ, Khamashta MA (2007) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 57:1487–1495

    Article  PubMed  Google Scholar 

  73. Cervera R, Asherson RA, Font J et al (1997) Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Med (Baltimore) 76:203–212

    Article  CAS  Google Scholar 

  74. D’Cruz DP, Mellor-Pita S, Joven B et al (2004) Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 31:280–285

    PubMed  Google Scholar 

  75. Heinlein AC, Gertner E (2007) Marked inflammation in catastrophic longitudinal myelitis associated with systemic lupus erythematosus. Lupus 16:823–826

    Article  CAS  PubMed  Google Scholar 

  76. Tarr T, Lakos G, Bhattoa HP et al (2007) Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 16:39–45

    Article  CAS  PubMed  Google Scholar 

  77. Hereng T, Lambert M, Hachulla E et al (2008) Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 17:11–15

    Article  CAS  PubMed  Google Scholar 

  78. Tektonidou MG, Laskari K, Panagiotakos DB et al (2009) Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61:29–36

    Article  PubMed  Google Scholar 

  79. Erkan D, Harrison MJ, Levy R et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56:2382–2391

    Article  CAS  PubMed  Google Scholar 

  80. Popescu A, Kao AH (2011) Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol 9:449–457

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Zandman-Goddard G, Blank M, Shoenfeld Y (2009) Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus 18:884–888

    Article  CAS  PubMed  Google Scholar 

  82. Navarrete MG, Brey RL (2000) Neuropsychiatric systemic lupus erythematosus. Curr Treat Options Neurol 2:473–485

    Article  PubMed  Google Scholar 

  83. Attal N, Bouhassira D (2015) Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain 156(Suppl 1):S104–S114

    Article  PubMed  Google Scholar 

  84. Bernatsky S, Boivin JF, Joseph L et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557

    Article  CAS  PubMed  Google Scholar 

  85. Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Med (Baltimore) 82:299–308

    Article  Google Scholar 

  86. Schwartz N, Goilav B, Putterman C (2014) The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 26:502–509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Dooley MA, Aranow C, Ginzler EM (2004) Review of ACR renal criteria in systemic lupus erythematosus. Lupus 13:857–860

    Article  CAS  PubMed  Google Scholar 

  88. Kasitanon N, Magder LS, Petri M (2006) Predictors of survival in systemic lupus erythematosus. Med (Baltimore) 85:147–156

    Article  Google Scholar 

  89. Alarcon GS, McGwin GJ, Petri M et al (2002) Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 11:95–101

    Article  CAS  PubMed  Google Scholar 

  90. Hahn BH, McMahon MA, Wilkinson A et al (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64:797–808

    Article  Google Scholar 

  91. Bihl GR, Petri M, Fine DM (2006) Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant 21:1749–1752

    Article  PubMed  Google Scholar 

  92. Giannico G, Fogo AB (2013) Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol 8:138–145

    Article  PubMed  Google Scholar 

  93. Weening JJ, D’Agati VD, Schwartz MM et al (2004) International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis: the classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530

    Article  PubMed  Google Scholar 

  94. KDIGO (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:221–232

    Article  Google Scholar 

  95. Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Tseng CE, Buyon JP, Kim M et al (2006) The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:3623–3632

    Article  CAS  PubMed  Google Scholar 

  97. Steinberg AD (1986) The treatment of lupus nephritis. Kidney Int 30:769–787

    Article  CAS  PubMed  Google Scholar 

  98. Gourley MF, Austin HA 3rd, Scott D et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125:549–557

    Article  CAS  PubMed  Google Scholar 

  99. Houssiau FA, Vasconcelos C, D’Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131

    Article  CAS  PubMed  Google Scholar 

  100. Houssiau FA, Vasconcelos C, D’Cruz D et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 6:61–64

    Article  CAS  Google Scholar 

  101. McKinley A, Park E, Spetie D et al (2009) Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin J Am Soc Nephrol 4:1754–1760

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Chan TM, Tse KC, Tang CS et al (2005) Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14:265–272

    Article  CAS  PubMed  Google Scholar 

  103. Petri M, Jones RJ, Brodsky RA (2003) High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 48:166–173

    Article  CAS  PubMed  Google Scholar 

  104. Monach PA, Arnold LM, Merkel PA (2010) Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 62:9–21

    Article  CAS  PubMed  Google Scholar 

  105. Somers EC, Marder W, Christman GM et al (2005) Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 5:2761–2767

    Article  CAS  Google Scholar 

  106. Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Isenberg D, Appel GB, Contreras G et al (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 49:128–140

    Article  Google Scholar 

  108. Henderson LK, Masson P, Craig JC et al (2013) Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 61:74–87

    Article  PubMed  Google Scholar 

  109. Henderson L, Masson P, Craig JC et al (2012) Treatment for lupus nephritis. Cochrane Database Syst Rev 12:CD002922

    PubMed  Google Scholar 

  110. Grootscholten C, Ligtenberg G, Hagen EC et al (2006) Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70:732–742

    Article  CAS  PubMed  Google Scholar 

  111. Grootscholten C, Bajema IM, Florquin S et al (2007) Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 56:924–937

    Article  CAS  PubMed  Google Scholar 

  112. Zavada J, Pesickova S, Rysava R et al (2010) Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 19:1281–1289

    Article  CAS  PubMed  Google Scholar 

  113. Liu Z, Zhang H, Liu Z et al (2015) Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162:18–26

    Article  PubMed  Google Scholar 

  114. Chen W, Tang X, Liu Q et al (2011) Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 57:235–244

    Article  CAS  PubMed  Google Scholar 

  115. Li X, Ren H, Zhang Q et al (2012) Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 27:1467–1472

    Article  CAS  PubMed  Google Scholar 

  116. Lewis EJ, Hunsicker LG, Lan SP et al (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 326:1373–1379

    Article  CAS  PubMed  Google Scholar 

  117. Euler HH, Schroeder JO, Harten P et al (1994) Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 37:1784–1794

    Article  CAS  PubMed  Google Scholar 

  118. Levy Y, Sherer Y, George J et al (2000) Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 29:321–327

    Article  CAS  PubMed  Google Scholar 

  119. Wenderfer SE, Thacker T (2012) Intravenous immunoglobulin in the management of lupus nephritis. Autoimmune Dis 2012:589359. doi:10.1155/2012/589359, Epub 2012 Sep 27

    PubMed  PubMed Central  Google Scholar 

  120. Ioannidis JP, Boki KA, Katsorida ME et al (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57:258–264

    Article  CAS  PubMed  Google Scholar 

  121. Grootscholten C, Berden JH (2006) Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 21:1465–1469

    Article  PubMed  Google Scholar 

  122. Laskari K, Tzioufas AG, Antoniou A et al (2011) Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. J Rheumatol 38:1304–1308

    Article  PubMed  Google Scholar 

  123. Yap DY, Ma MK, Mok MM et al (2013) Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 52:480–486

    Article  CAS  Google Scholar 

  124. Bomback AS, Appel GB (2010) Updates on the treatment of lupus nephritis. J Am Soc Nephrol 21:2028–2035

    Article  CAS  PubMed  Google Scholar 

  125. Dooley MA, Jayne D, Ginzler EM et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886–1895

    Article  CAS  PubMed  Google Scholar 

  126. Houssiau FA, D’Cruz D, Sangle S et al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 69:2083–2089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Morris HK, Canetta PA, Appel GB (2013) Impact of the ALMS and Maintain trials on the management of lupus nephritis. Nephrol Dial Transplant 28:1371–1376

    Article  CAS  PubMed  Google Scholar 

  128. Moroni G, Doria A, Mosca M et al (2006) A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 1:925–932

    Article  CAS  PubMed  Google Scholar 

  129. Griffiths B, Emery P, Ryan V et al (2010) The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 49:723–732

    Article  CAS  Google Scholar 

  130. Contreras G, Pardo V, Leclercq B et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980

    Article  CAS  PubMed  Google Scholar 

  131. Gibson KL, Gipson DS, Massengill SA et al (2009) Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol 4:1962–1967

    Article  PubMed  PubMed Central  Google Scholar 

  132. Roccatello D, Sciascia S, Rossi D et al (2011) Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 26:3987–3992

    Article  CAS  PubMed  Google Scholar 

  133. Davies RJ, Sangle SR, Jordan NP et al (2013) Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 22:574–582

    Article  CAS  PubMed  Google Scholar 

  134. Gunnarsson I, Jonsdottir T (2013) Rituximab treatment in lupus nephritis – where do we stand? Lupus 22:381–389

    Article  CAS  PubMed  Google Scholar 

  135. Rauova L, Lukac J, Levy Y et al (2001) High-dose intravenous immunoglobulins for lupus nephritis – a salvage immunomodulation. Lupus 10:209–213

    Article  CAS  PubMed  Google Scholar 

  136. Ogawa H, Kameda H, Amano K et al (2010) Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 19:162–169

    Article  CAS  PubMed  Google Scholar 

  137. Miyasaka N, Kawai S, Hashimoto H (2009) Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 19:606–615

    Article  CAS  PubMed  Google Scholar 

  138. Gordon S, Denunzio T, Uy A (2013) Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria. Hawaii J Med Public Health 72(9 Suppl 4):18–23

    PubMed  PubMed Central  Google Scholar 

  139. Mandell BF (1987) Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 17:126–141

    Article  CAS  PubMed  Google Scholar 

  140. Doria A, Iaccarino L, Sarzi-Puttini P et al (2005) Cardiac involvement in systemic lupus erythematosus. Lupus 14:683–686

    Article  CAS  PubMed  Google Scholar 

  141. Miner JJ, Kim AH (2014) Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 40:51–60

    Article  PubMed  Google Scholar 

  142. Man BL, Mok CC (2005) Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus 14:822–826

    Article  CAS  PubMed  Google Scholar 

  143. Rosenbaum E, Krebs E, Cohen M et al (2009) The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: a retrospective study and literature review. Lupus 18:608–612

    Article  CAS  PubMed  Google Scholar 

  144. Apte M, McGwin G Jr, Vilá LM et al (2008) Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort (LV). [corrected]. Rheumatology (Oxford) 47:362–367

    Article  CAS  Google Scholar 

  145. Schattner A, Liang MH (2003) The cardiovascular burden of lupus: a complex challenge. Arch Intern Med 163:1507–1510

    Article  PubMed  Google Scholar 

  146. Zawadowski GM, Klarich KW, Moder KG et al (2012) A contemporary case series of lupus myocarditis. Lupus 21:1378–1384

    Article  CAS  PubMed  Google Scholar 

  147. Micheloud D, Calderón M, Caparrros M, D’Cruz DP (2007) Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann Rheum Dis 66:986–987

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Moyssakis I, Tektonidou MG, Vasilliou VA et al (2007) Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 120:636–642

    Article  PubMed  Google Scholar 

  149. Roldan CA, Qualls CR, Sopko KS, Sibbitt WL Jr (2008) Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol 35:224–229

    PubMed  Google Scholar 

  150. Zuily S, Regnault V, Selton-Suty C et al (2011) Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 124:215–224

    Article  CAS  PubMed  Google Scholar 

  151. Bartels CM, Buhr KA, Goldberg JW et al (2014) Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 41:680–787

    Article  PubMed  PubMed Central  Google Scholar 

  152. Schoenfeld SR, Kasturi S, Costenbader KH (2013) The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 43:77–95

    Article  PubMed  Google Scholar 

  153. Riboldi P, Gerosa M, Meroni PL (2005) Statins and autoimmune diseases. Lupus 14:765–768

    Article  CAS  PubMed  Google Scholar 

  154. Tu H, Li Q, Xiang S et al (2012) Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Atherosclerosis 222:29–33

    Article  CAS  PubMed  Google Scholar 

  155. Mittoo S, Fell CD (2014) Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 35:249–254

    Article  PubMed  Google Scholar 

  156. Keane MP, Lynch JP 3rd (2000) Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 55:159–166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Kobayashi A, Okamoto H (2012) Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol 5:219–227

    Article  CAS  PubMed  Google Scholar 

  158. Badsha H, Teh CL, Kong KO et al (2004) Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 33:414–421

    Article  PubMed  Google Scholar 

  159. Virdi RP, Bashir A, Shahzad G et al (2012) Diffuse alveolar hemorrhage: a rare life-threatening condition in systemic lupus erythematosus. Case Rep Pulmonol 2012:836017. doi:10.1155/2012/836017, Epub 2012 May 27

    PubMed  PubMed Central  Google Scholar 

  160. Schwab EP, Schumacher HR Jr, Freundlich B, Callegari PE (1993) Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 23:8–15

    Article  CAS  PubMed  Google Scholar 

  161. Erickson RW, Franklin WA, Emlen W (1994) Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 24:114–123

    Article  CAS  PubMed  Google Scholar 

  162. Calderaro DC, Ferreira GA (2012) Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases. Rheumatol Int 32:1391–1396

    Article  PubMed  Google Scholar 

  163. Karim MY, Miranda LC, Tench CM et al (2002) Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum 31:289–298

    Article  PubMed  Google Scholar 

  164. Pope J (2008) An update in pulmonary hypertension in systemic lupus erythematosus – do we need to know about it? Lupus 17:274–277

    Article  CAS  PubMed  Google Scholar 

  165. Prabu A, Gordon C (2013) Pulmonary arterial hypertension in SLE: what do we know? Lupus 22:1274–1285

    Article  CAS  PubMed  Google Scholar 

  166. Jais X, Launay D, Yaici A et al (2008) Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 58:521–531

    Article  PubMed  Google Scholar 

  167. Provencher S, Granton JT (2015) Current treatment approaches to pulmonary arterial hypertension. Can J Cardiol 31:460–477

    Article  PubMed  Google Scholar 

  168. Carmier D, Marchand-Adam S, Diot P, Diot E (2010) Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir 27:e66–e78

    Article  CAS  PubMed  Google Scholar 

  169. Ebert EC, Hagspiel KD (2011) Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 45:436–441

    Article  CAS  PubMed  Google Scholar 

  170. Tian XP, Zhang X (2010) Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment. World J Gastroenterol 16:2971–2977

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Janssens P, Arnaud L, Galicier L et al (2013) Lupus enteritis: from clinical findings to therapeutic management. Orphanet J Rare Dis 8:67. doi:10.1186/1750-1172-8-67

    Article  PubMed  PubMed Central  Google Scholar 

  172. Law ST, Ma KM, Li KK (2012) The clinical characteristics of lupus related protein-losing enteropathy in Hong Kong Chinese population: 10 years of experience from a regional hospital. Lupus 21:840–847

    Article  CAS  PubMed  Google Scholar 

  173. García López CA, Laredo-Sánchez F, Malagón-Rangel J et al (2014) Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge. World J Gastroenterol 20:11443–11450

    Article  PubMed  PubMed Central  Google Scholar 

  174. Nesher G, Breuer GS, Temprano K et al (2006) Lupus-associated pancreatitis. Semin Arthritis Rheum 35:260–267

    Article  PubMed  Google Scholar 

  175. Liu R, Zhang L, Gao S et al (2014) Gastrointestinal symptom due to lupus peritonitis: a rare form of onset of SLE. Int J Clin Exp Med 7:5917–5920

    PubMed  PubMed Central  Google Scholar 

  176. Beisel C, Weiler-Normann C, Teufel A, Lohse AW (2014) Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature. World J Gastroenterol 20:12662–12667

    Article  PubMed  PubMed Central  Google Scholar 

  177. Fayyaz A, Igoe A, Kurien BT et al (2015) Haematological manifestations of lupus. Lupus Sci Med 2(1):e000078

    Article  PubMed  PubMed Central  Google Scholar 

  178. Petri M, Orbai AM, Alarcón GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686

    Article  PubMed  PubMed Central  Google Scholar 

  179. Euler HH, Harten P, Zeuner RA et al (1997) Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 24:2153–2157

    CAS  PubMed  Google Scholar 

  180. Arnal C, Piette JC, Leone J et al (2002) Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 29:75–83

    CAS  PubMed  Google Scholar 

  181. Roach BA, Hutchinson GJ (1993) Treatment of refractory, systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide. Arthritis Rheum 36:682–684

    Article  CAS  PubMed  Google Scholar 

  182. Roldan R, Roman J, Lopez D et al (1994) Treatment of hemolytic anemia and severe thrombocytopenia with high-dose methylprednisolone and intravenous immunoglobulins in SLE. Scand J Rheumatol 23:218–219

    Article  CAS  PubMed  Google Scholar 

  183. Sakamoto H, Takaoka T, Usami M et al (1985) Apheresis: clinical response to patients unresponsive to conventional therapy. Trans Am Soc Artif Intern Organs 31:704–770

    CAS  PubMed  Google Scholar 

  184. Lateef A, Lahiri M, Teng GG et al (2010) Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus 19:765–770

    Article  CAS  PubMed  Google Scholar 

  185. Hakim AJ, Machin SJ, Isenberg DA (1998) Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. Semin Arthritis Rheum 28:20–25

    Article  CAS  PubMed  Google Scholar 

  186. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M et al (2013) Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 121:537–545

    Article  CAS  PubMed  Google Scholar 

  187. Gomard-Mennesson E, Ruivard M, Koenig M et al (2006) Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 15:223–231

    Article  CAS  PubMed  Google Scholar 

  188. Alba P, Karim MY, Hunt BJ (2003) Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 12:633–635

    Article  CAS  PubMed  Google Scholar 

  189. Letchumanan P, Thumboo J (2011) Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. Semin Arthritis Rheum 40:298–306

    Article  CAS  PubMed  Google Scholar 

  190. Abdwani R, Mani R (2009) Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. Lupus 18:460–464

    Article  CAS  PubMed  Google Scholar 

  191. Nesher G, Hanna VE, Moore TL et al (1994) Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 24:165–172

    Article  CAS  PubMed  Google Scholar 

  192. Zandman-Goddard G, Levy Y, Shoenfeld Y (2005) Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 29:219–228

    Article  CAS  PubMed  Google Scholar 

  193. Arıcı ZS, Batu ED, Ozen S (2015) Reviewing the recommendations for lupus in children. Curr Rheumatol Rep 17:17

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SCDU Nephrology and Dialysis, Giovanni Bosco Hospital, Piazza del donatore di Sangue 3, Turin, 10154, Italy

    Giacomo Quattrocchio & Dario Roccatello

  2. Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA

    Fernando Fervenza

  3. Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, S. Giovanni Bosco Hospital Turin, Piazza del donatore di Sangue 3, Torino, 10154, Italy

    Dario Roccatello

Authors
  1. Giacomo Quattrocchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernando Fervenza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dario Roccatello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dario Roccatello .

Editor information

Editors and Affiliations

  1. Giovanni Bosco Hospital, Center of Immunopathology/Rare Dise, Torino, Torino, Italy

    Dario Roccatello

  2. University of Florence, Florence, Italy

    Lorenzo Emmi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Quattrocchio, G., Fervenza, F., Roccatello, D. (2016). Conventional Treatment of Systemic Lupus Erythematosus. In: Roccatello, D., Emmi, L. (eds) Connective Tissue Disease. Rare Diseases of the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-319-24535-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-24535-5_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-24533-1

  • Online ISBN: 978-3-319-24535-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation